Skip to Content

Posts tagged with "Clinical Trials"

  • Alzheimer's Disease

    Merck Presses Ahead on Alzheimer’s:

    One Alzheimer’s compound recently died off in the clinic – Bristol-Myers Squibb’s avagacestat, a gamma-secretase inhibitor, has been pulled from trials. The compound “did not establish a profile that supported advancement” to Phase III, says the company. Gamma-secretase has been a troubled area for some time, highlight… Read More
  • Alzheimer's Disease

    TauRx Goes Into Phase III For Alzheimer’s

    I can’t even count the number of e-mails I’ve gotten over the last few years asking about TauRx and their Alzheimer’s program, which made a big splash back in 2008. Finally, there’s some news to report. The company is starting Phase III clinical trials, and has announced new financing to see these through. The company… Read More
  • Alzheimer's Disease

    And Since We’re Talking About Insider Trading

    Here’s something from just this morning, a whopping large case on illegal trading in Wyeth and Elan stock. This one involves a hedge fund manager, Mathew Martoma, and (quite disturbingly), Dr. Sidney Gilman of the University of Michigan, who was the lead investigator on a very large bapineuzumab trial for Alzheimer’s. His conduct appear… Read More
  • Clinical Trials

    Oh Yeah, Now That You Mention It, They’re Dead

    The overhyped nature of stem cell therapies is a topic that’s come up here several times. In the latest developments, Pluristem, Inc., is threatening to sue Bloomberg New for their recent report, titled “Girl Dies As Pluristem Sells On Gains With Miracle Cells”. Gosh, it’s hard to see why the company would take exception to… Read More
  • Alzheimer's Disease

    The Coming Battle Over Alzheimer’s Disease

    Solanezumab is a story that won’t go away. Eli Lilly’s antibody therapy for Alzheimer’s is the subject of a lot of arguing among investors: some people (and I’m one of them) think that there is no strong evidence for its efficacy, not yet, and that the amount of time and effort devoted to finding that… Read More
  • Business and Markets

    “Basically, They’re A Bunch of Lemmings”

    True, but that’s unfair to lemmings. This is Raghuram Selveraju of Aegis Capital, talking about deal-making executives in the big pharma companies and the string of costly blowups so far this year. That link has the list, and it’s quite an impressive string of fireballs. “What all of these deals had in common was the… Read More
  • Clinical Trials

    The Generic Wellbutrin Problem: Whose Fault Is It?

    One of the questions I get asked most often, by people outside of the drug industry, is whether generic medications really are the same as the original branded ones. My answer has always been the same: that yes, they are. And that’s still my answer, but I’ll have to modify it a bit, because we’re… Read More
  • Alzheimer's Disease

    Another Prospective Alzheimer’s Trial

    I wrote here about a prospective Alzheimer’s trial that’s starting soon among a population in Colombia, and now comes word of another large effort along the same lines. DIAN, the Dominantly Inherited Alzheimer’s Network, will test several current Alzheimer’s candidates in groups of people around the world with genetic mutati… Read More
  • Clinical Trials

    GSK Opens Up Its Trial Data

    GlaxoSmithKline took an unusual step today: they announced that they’re opening up clinical trial data: “GSK is fully committed to sharing information about its clinical trials. It posts summary information about each trial it begins and shares the summary results of all of its clinical trials – whether positive or negative – on a w… Read More
  • Alzheimer's Disease

    Lilly’s Solanezumab: Did It Actually Work?

    “Hope Rises For Alzheimer’s Treatment, Scientists Say”. Not this scientist. That’s a composite of headlines, but it captures the unfortunate tone. We’re talking about solanezumab, Eli Lilly’s antibody therapy. The company presented analysis of their trial data yesterday, and put a very optimistic face on things.… Read More